Litcius/Paper detail

Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE)

Alexandre Duvignaud, Edouard Lhomme, Racha Onaisi, Rémi Sitta, Ambre Gelley, Julie Chastang, Lionel Piroth, Christine Binquet, Julie Dupouy, Alain Makinson, Benjamin Lefèvre, Jean‐Marc Naccache, Caroline Roussillon, Roland Landman, Cédrick Wallet, Sophie Karcher, Valérie Journot, Duc Nguyen, Thierry Pistone, Stéphane Bouchet, Marie‐Edith Lafon, Mathiéu Molimard, Rodolphe Thiébaut, Xavier de Lamballerie, Jean-Philippe Joseph, Laura Richert, Olivier Saint‐Lary, Sarah Djabarouti, Linda Wittkop, Xavier Anglaret, Denis Malvy

2022Clinical Microbiology and Infection35 citationsDOIOpen Access PDF

Topics & Concepts

CiclesonideInterquartile rangeMedicineAdverse effectRandomized controlled trialEmergency medicineInternal medicineAsthmaInhaled corticosteroidsPharmacological Receptor Mechanisms and EffectsLong-Term Effects of COVID-19COVID-19 Clinical Research Studies
Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE) | Litcius